(PharmaNewsWire.Com, December 05, 2018 ) Pancreatic Cancer-Disease Understanding and Treatment Algorithm According to National Cancer Institute, "Pancreatic Cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas". It starts when cells in the pancreas start to grow out of control and spreads rapidly to nearby organs. As the symptoms of pancreatic cancer in the early stage are unnoticeable, it is getting difficult to detect and diagnose it early.
The Publisher Pancreatic Cancer market report gives the thorough understanding of the Pancreatic Cancer by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pancreatic Cancer in the US, Europe, and Japan.
Pancreatic Cancer Epidemiology The Pancreatic Cancer epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Publisher report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Sex Specific Prevalence, Stage Specific Prevalence and Diagnosed and Treatable population] scenario of Pancreatic Cancer in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027. According to Cancer Research UK, in males in the UK, pancreatic cancer is the 12th most common cancer (3% of all new male cancer cases). In females in the UK it is the 9th most common cancer (3% of all new female cancer cases).
Pancreatic Cancer Drug Chapters This segment of the Pancreatic Cancer report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The treatment of pancreatic cancer depends upon the stage of the cancer, whether it is in the pancreas, and whether it's spread to any of the surrounding organs and blood vessels. The treatment may include surgery, chemotherapy, radiation or combination of these. Some of the FDA approved drugs for the treatment of pancreatic cancer are Tarceva (erlotinib), Onivyde (irinotecan liposome injection), Gemzar (gemcitabine HCL). In January 2018, Food & Drug Administration (FDA) had approved Lutathera, for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including pancreatic neuroendocrine tumors (PNETs).
Pancreatic Cancer Market Outlook The Pancreatic Cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. Key players such as Dexcel Pharma Technologies, Yuhan Corporation and many other are involved in developing therapies for Periodontal Disease. Expected launch of emerging therapies such as Perio Chip (Dexcel Pharma Technologies), YH23537 (Yuhan Corporation) and other therapies will significantly impact the Periodontal Disease market during the study period (2016-2027).
Pancreatic Cancer Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Pancreatic Cancer Report Insights -Patient Population -Therapeutic Approaches -Pipeline Analysis -Market Size and Trends -Market Opportunities -Impact of upcoming Therapies
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
